The Economic Burden of Coronary Heart Disease in Iran: A Bottom-up Approach in 2014

Abstract

Background & objectives: cardiovascular diseases are the main cause of mortality around the whole world. However, there is limited information on its economic costs in Iran. The aim of this study was to evaluate the economic costs of coronary heart disease in Iran in 2014. Methods: The diseases costs were calculated based on the incidence approach using a bottomup method and a community-oriented perspective. The drug cost information was obtained from angiographed patients (607 cases) in Shahid Modarres Hospital using simple random sampling method. Other information like disease incidence, distribution of patients, treatment patterns, length of stay and mortality rate was gathered from the literature, interview with patients, consultation with specialists, questionnaire, ministry of health and statistical center of Iran. Results: Coronary heart diseases impose a significant economic burden in the range of 4,715 and 4,908 billion dollars (210,037,860,000,000-201,778,425,000,000 rials) upon Iran economic system. The medical costs and the costs of lost productivity due to premature death were calculated at USD 3.572 billion (152,863,740,000,000 rials) and USD 933 million (39,927,735,000,000 rials) respectively. The major part of medical costs was related to angioplasty costs (47%) and the minor part was related to drug costs (1.15%). Conclusion: Coronary heart diseases impose a lot of financial costs to Iran healthcare system which cover more than 16% of whole healthcare financial costs. It is possible to streamline all consequential costs due to coronary heart disease by means of economic and effective use of resources and widespread self-care plan.

The impact of general and central obesity for all-cause hospitalization among Iranian adults: a 20 year follow-up-results from the TLGS cohort

“…Previous studies in our country have shown that the average BMI of Iranian adults has increased over the past two decades [ 27 ], and that about 60% of Iranian adults are overweight or obese [ 5 ]. On the other hand, in 2014, CHD contributed more than 16% of whole healthcare financial costs in Iran [ 28 ]. Moreover, healthcare costs has increased substantially in recent years [ 29 ], hence, it is expected that the economic cost of CHD to be much higher now, and will continue to rise for decades.…”

Economic Evaluation of Hypertension screening in Iran using Markov model

“…Direct medical costs, encompassing high blood pressure diagnosis and treatment, along with costs related to selected diseases, Direct medical costs of selected diseases were calculated using health insurance data, survey(26) and a literature review(24, 27, 28), and Direct non-medical costs Using a literature review were calculated (27, 28). and indirect costs were calculated using the human capital approach Using the NASBOD and IHME database for Global Burden of Disease (22, 29).…”

Cardiovascular diseases preventive policy‐making process in Iran: A framework‐based policy analysis

“…It should be noted that CVD is costly in the Iranian health care system. Health policymakers can limit the costs and consequences of the disease by using resources efficiently and effectively and expanding self-care and screening programs (Raghfar et al, 2018). The burden of NCDs is associated with poverty and serves as a barrier in achieving sustainable development goals (Nugent et al, 2018).…”